Novartis CEO Issues Staunch Defense of Zolgensma As Sales Soar

The Swiss major has got off to a strong start in 2019 with Cosentyx and Entresto sales soaring and Mayzent – and possibly very soon Zolgensma – getting US approvals.

Desk
Numbers adding up nicely at Novartis • Source: Shutterstock

Novartis AG CEO Vas Narasimhan has said that US approval of Zolgensma for spinal muscular atrophy remains on track for May following patient deaths that he believes have led to "misleading or mis-characterized headlines" concerning the safety of the closely watched gene therapy.

Narasimhan was speaking to journalists early this morning (24 April) on a call about Novartis's first quarter 2019 financials and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business